Johnson & Johnson pause COVID-19 Vaccine Trial After “Unexplained Illness" in study participant

The Phase III study, which began on 23 September, is intended to investigate use in 60,000 adults and enrolling in the U.S. Argentina, Brazil, Chile, Colombia, Mexico, Peru and South Africa. The unexplained illness has not been disclosed.

Source:

Biospace Inc.